Shield reports top-line results from pivotal Phase III study of Feraccru®

5 Feb 2018

Shield reports top-line results from pivotal Phase III study of Feraccru® (Ferric Maltol) in the treatment of IDA in patients with CKD. For more information please see the attached press release.

STX_Results_CKD Phase3 FINAL

 

Back to news